COST-EFFECTIVENESS OF DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION MANAGEMENT IN COLOMBIA

被引：0
|
作者：
Alfonso-Cristancho, R. [1 ]
Herran, S. [2 ]
Caicedo, M. [2 ]
Gomez, E. [3 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] RANDOM Fdn, Bogota, DC, Colombia
[3] Clin Shaio, Bogota, Colombia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1525
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A536 / A537
页数：2
相关论文
共 50 条
  • [1] DABIGATRAN VERSUS WARFARIN FOR ATRIAL FIBRILLATION IN COLOMBIA
    Alfonso-cristancho, R.
    Vecino, A., I
    Herran, S.
    VALUE IN HEALTH, 2012, 15 (04) : A121 - A121
  • [2] Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
    Freeman, James V.
    Zhu, Ruo P.
    Owens, Douglas K.
    Garber, Alan M.
    Hutton, David W.
    Go, Alan S.
    Wang, Paul J.
    Turakhia, Mintu P.
    ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) : 1 - U129
  • [3] Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
    Davidson, Thomas
    Husberg, Magnus
    Janzon, Magnus
    Oldgren, Jonas
    Levin, Lars-Ake
    EUROPEAN HEART JOURNAL, 2013, 34 (03) : 177 - 183
  • [4] Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
    Clemens, Andreas
    Peng, Siyang
    Brand, Sarah
    Brueckmann, Martina
    Kansal, Anuraag
    Lim, Jonathan
    Noack, Herbert
    Sander, Stephen
    Sorensen, Sonja
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (06): : 849 - 855
  • [5] Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
    You, Joyce H. S.
    Tsui, Kia K. N.
    Wong, Raymond S. M.
    Cheng, Gergory
    PLOS ONE, 2012, 7 (06):
  • [6] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    STROKE, 2013, 44 (06) : 1676 - +
  • [7] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [8] Improve Warfarin Therapy or Use Dabigatran for Patients with Atrial Fibrillation - A Cost-Effectiveness Analysis
    You, Joyce H.
    Tsui, Kia K.
    Wong, Raymond S.
    Cheng, Gregory
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (09): : 1334 - 1334
  • [9] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [10] A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
    Sorensen, Sonja V.
    Peng, Siyang
    Monz, Brigitta U.
    Bradley-Kennedy, Carole
    Kansal, Anuraag R.
    PHARMACOECONOMICS, 2013, 31 (07) : 589 - 604
12345